BioAge Labs (BIOA) vs Canopy Growth (CGC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Canopy Growth (CGC) over the past year, gaining 11.8% versus a loss of 39.6%. Canopy Growth is the larger company by market cap ($380.5 million vs $285.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | CGC |
|---|---|---|
| Share price | $6.21 | $0.8468 |
| Market cap | $285.02M | $380.47M |
| 1-day change | -0.80% | -3.39% |
| YTD return | -52.68% | -23.11% |
| 1-year return | +11.79% | -39.55% |
| 5-year return | — | -99.34% |
| EPS (TTM) | $-2.39 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $2.38 |
| 52-week low | $5.04 | $0.81 |
| Distance from 52-week high | -76.07% | -64.42% |
| Analyst consensus | none | none |
| Avg. price target upside | +473.75% | +40.53% |
| Average volume | 913.77K | 2.75M |
| Shares outstanding | 45.90M | 423.04M |
| Employees | 60 | 1,128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed CGC by 51.3 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Health Care · Medicinal Chemicals and Botanical Products · 1,128 employees
BIOA vs CGC FAQ
Which is bigger, BioAge Labs or Canopy Growth?
Canopy Growth (CGC) is larger, with a market capitalization of $380.47M compared with $285.02M for BioAge Labs (BIOA).
Which stock has performed better over the past year, BIOA or CGC?
BIOA returned +11.79% over the past 12 months, compared with -39.55% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Canopy Growth in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for BioAge Labs and Medicinal Chemicals and Botanical Products for Canopy Growth.